pharma · Diabetes Mellitus · Hemophilia A
Takeda
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
TAK-620-2004
Phase 3 · small molecule · Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)
TAK-620-2004 for Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT) is a Phase 3 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Internal code TAK-620-2004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Takeda
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)
- Status
- active
- Trials
- 1